<DOC>
	<DOCNO>NCT02001363</DOCNO>
	<brief_summary>The investigator plan research cardioprotective effect intravenous liraglutide reperfusion injury .</brief_summary>
	<brief_title>Efficacy Study Glucagonlike Peptide-1 Treat Reperfusion Injury</brief_title>
	<detailed_description>Acute myocardial infarction major cause mortality morbidity . Primary percutaneous coronary intervention ( pPCI ) currently effective treatment strategy acute myocardial infarction . However , sizable number patient fail restore optimal myocardial reperfusion , mostly 'no-reflow ' phenomenon . Glucagon-like peptide-1 ( GLP-1 ) incretin hormone regulate plasma glucose , recently GLP-1 analogue introduce treatment type-2 diabetes . In experimental study , GLP-1 analogue protect reperfusion injury-induced cell death . Exenatide reduce reperfusion injury patient ST-segment elevation myocardial infarction . Liraglutide ( GLP-1 ) safe effective reduce weight , serum lipid level blood pressure . Liraglutide reduce cardiac rupture ( 12 60 versus 46 60 ; P=0.0001 ) infarct size ( 21±2 % versus 29±3 % , P=0.02 ) improve cardiac output ( 12.4±0.6 versus 9.7±0.6 ml/min ; P=0.002 ) normal diabetic mouse . The investigator plan research cardioprotective effect intravenous liraglutide administer prior reperfusion continue restoration coronary blood flow patient STEMI undergo pPCI .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Patients eligible 18 year older present within 12 h onset symptom sign STsegment elevation myocardial infarction catheterization laboratory . The patient consider enrolment present unconsciousness , cardiogenic shock , hypoglycaemia , diabetic ketoacidosis , previous myocardial infarction , stent thrombosis , know renal insufficiency , previous coronary artery bypass operation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Reperfusion injury</keyword>
	<keyword>Liraglutide</keyword>
</DOC>